AML scientists have extensive experience in the development of CLIA-validated IHC assays, pharmDx IHC assays, and IHC-based companion diagnostics. AML has on-site pathologists to assist with the optimization and standardization of new IHC targets.

  • AML possesses a comprehensive collection of IHC assays.
  • AML consistently incorporates new IHC assays with a rapid validation time.
  • AML works with clients to develop custom IHC assays, and AML offers solutions to optimize existing IHC assays.
  • Our group has a strong history of LDT and companion diagnostic development (most recently the standardization and harmonization of IHC PD-L1 companion diagnostics).

American Molecular Laboratories has observed that the most reliable and consistent IHC studies are performed with single or dual antibody staining.
Examples of previous oncology-related IHC assays are shown in Table 1.

Table 1.  Immunohistochemistry Tests (truncated list)

 Cleaved Caspase 3 (CC3) HER2
 cMYC HIF-1a
EGFR MMP-12
 ER IHC MMP-19
 HER3 MMP-3
 HER4 MMP-3
 HercepTest MMP-7
 Ki-67 NRF2
 MDR1 OCT1
 p-Erk (T202/Y204) OCT2
AKT
CD20 p-AKT (S473)
CD4 p-c-JUN (S63)
CD8 p-cMET (Y1234/1235)
c-JUN PD-1
cKIT PDGFRbeta
Cleaved PARP (cPARP) PD-L1
cMET p-gH2A.X (S139)
CTLA4 pPRAS40 (T246)
DNMT-1 pRSK (S3380)
FOXP3 pS6 (S240/244)
Galectin-3 PR
Gli-1 Stathmin

Figure Legend.  AML’s Comprehensive tumor profiling combines Next-Generation Sequencing (NGS) and Immunohistochemistry to analyze the underlying biology of cancer.